Naganuma M, Shiga H, Shimoda M, Matsuura M, Takenaka K, Fujii T, Yamamoto S, Matsubayashi M, Kobayashi T, Aoyama N, et al. First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study. Journal of Gastroenterology. 2025. 60. 4. 430-441
Okabe M, Yamamoto S, Shiokawa M, Hisamatsu T, Yamazaki H, Nakanishi R, Hamada K, Kitamoto H, Kuwada T, Uza N, et al. Anti-integrin αvβ6 antibody as a biomarker for diagnosing ulcerative colitis: a nationwide multicenter validation study. Journal of Gastroneterology. 2024. 60. 86-95
Danese S, Dignass A, Matsuoka K, Ferrante M, Long M, Redondo I, Moses R, Maier S, Hunter Gibble T, Morris N, et al. Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme. journal of crohn's and colitis. 2024. 18. 1845-1856
Feagan BG, Matsuoka K, Rogler G, Laharie D, Vermeire S, Danese S, Loftus EV Jr, Beales I, Schreiber S, Kim HJ, et al. Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study. Alimentary pharmacology & therapeutics. 2024. 60. 5. 563-584
Matsuoka K, Inoue T, Tsuchiya H, Nagano K, Iwahori T. Association between oral corticosteroid starting dose and the incidence of pneumonia in Japanese patients with ulcerative colitis: a nation-wide claims database study. Intestinal Research. 2024. 22. 3. 319-335
